Rheumatoid arthritis treatment
T-cell autoimmunotherapy relieves joint inflammation and restores mobility by targeting the immune root of the disease — without suppressing overall immunity.
T-cell immunotherapy for rheumatoid arthritis
Rheumatoid arthritis is caused by an autoimmune process that destroys the joint surface. Pro-inflammatory T-lymphocytes reactive to cartilage antigens play the leading role.
Standard protocols prescribe anti-inflammatory drugs, and in severe cases, glucocorticoids and immunomodulators. These agents are toxic, cause hormonal imbalances and immune decline, and do not address the root of the disease.
T-cell autovaccination draws on the body's own mechanism for regulating immunity: it stimulates anti-idiotypic reactions aimed selectively at inactivating pathogenic idiotype-bearing T-lymphocytes, without suppressing immunity as a whole.
How the method works
T-cell autovaccination acts selectively: it switches off the pathogenic lymphocytes and leaves the rest of the immune system alone.
Cell collection and isolation
Autoaggressive T-lymphocytes involved in joint tissue damage are isolated from your blood.
Autoaggressive T-lymphocytes involved in joint tissue damage are isolated from your blood.
Vaccine preparation
The isolated cells are activated and used to create a personalized T-cell vaccine.
The isolated cells are activated and used to create a personalized T-cell vaccine.
Selective suppression
Vaccination triggers a regulatory immune response that suppresses specifically the pathogenic cell clones, reducing inflammation.
Vaccination triggers a regulatory immune response that suppresses specifically the pathogenic cell clones, reducing inflammation.
Parameter monitoring
Pro-inflammatory activity (ESR, CRP, TNF-α, IL-6) decreases while anti-inflammatory activity increases — without overall immune suppression.
Pro-inflammatory activity (ESR, CRP, TNF-α, IL-6) decreases while anti-inflammatory activity increases — without overall immune suppression.
Clinical Study Results
Dynamics of the main parameters during T-cell autoimmunotherapy over 24 months of observation.
DAS28 activity index
transition to a low disease activity zone
ESR, mm/h
reduction of the inflammation marker
Hemoglobin, g/L
restoration of blood parameters
Change in indicators over 24 months
| Indicator | Baseline (0 mo) | At 24 mo |
|---|---|---|
| ESR, mm/h | 38.4 | 21.1 |
| Hemoglobin, g/L | 107.8 | 126.5 |
| DAS28 (disease activity) | 5.92 | 3.12 |
P < 0.001 — statistically significant difference before and after treatment initiation (U-test). Positive dynamics persisted steadily throughout the entire observation period (3, 6, 12, 16, and 24 months).
Advantages of the therapy
Addressing the root cause
The method targets faulty autoimmune mechanisms, rather than simply suppressing symptoms.
No immunosuppression
General immunity is not depressed; no significant side effects have been identified.
Restoration of blood metrics
Pro-inflammatory activity decreases while anti-inflammatory agents (regulatory T-cells, IL-4, IL-10) increase.
Cost-effective
The method doesn't require knowledge of autoantigens or prolonged cell cultivation, making it several times more affordable than humanized antibody drugs.
When the method is effective
A distinct clinical effect is achieved not only in early but also in advanced stages of rheumatoid arthritis.
Improvement of varying degree has been recorded in most of the vaccinated patients.
The method's mechanisms are validated and confirmed in peer-reviewed scientific publications, including international journals.
Answers to questions about the therapy
Does the method have side effects?
Due to immune system stimulation, a slight rise in temperature may occur after the initial vaccines. It is short-lived and passes without antipyretics.
How quickly does joint pain subside?
After the vaccination course, pain during joint stress and movement stiffness disappear.
How long does the remission last?
From two to five years. In the event of a relapse, the form of the disease becomes significantly less aggressive.
How often does the therapy need to be repeated?
Usually, two or three courses are enough for a stable remission. The regimen is chosen by the doctor individually.
Where to go next
Other conditions in this area
Cost of the course
Doctors in this area
Discuss your situation
Leave your contact details. Our medical coordinator will contact you shortly to answer any questions.